Dexcom, a global leader in glucose biosensing, announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Boehnlein brings over 20 years of experience in the medical technology industry, having previously served as Vice President and CFO of Stryker Corporation. His expertise in financial leadership, capital allocation, and strategic M&A is expected to be invaluable as Dexcom executes its long-range plan.

ARC Group Acquisition I Corp (NASDAQ:ARCL) has announced a definitive share purchase agreement to acquire Firstborn Top Capital Sdn. Bhd., a Malaysian private financing company, for approximately $1.09 billion. Upon completion, ARCL will be renamed BlueCrest Investment, Inc. and is expected to list on the Nasdaq Global Market under the ticker symbol BCIN. The transaction is projected to close in the first quarter of 2027 and aims to expand Firstborn Top Capital's market reach and lending capabilities.

Lorence H. Kim, a director at Revolution Medicines, Inc. (NASDAQ:RVMD), sold 17,190 shares of common stock totaling $3,585,836 on September 8, 2026, through a 10b5-1 trading plan. These sales occurred at weighted average prices ranging from $206.6049 to $212.2693, following a significant surge in the company's stock price. After these transactions, the Lorence Kim Revocable Trust no longer holds shares, though Kim retains 1,191 shares directly, including restricted stock units.

A resident of Erie, Colorado, Selena Maranjian, expresses concerns about the Draco fracking project and the Town Council's handling of related mineral rights deals with SM Energy. Maranjian highlights SM Energy's environmental violations and urges fellow Erie residents to prioritize health and safety over potential financial gains from oil and gas operations. The letter also encourages active participation in upcoming town council elections to vote for candidates opposing such operations.

Omnicom Group (NYSE: OMC) stock closed up 1.5% on September 10, 2026, reaching USD 79.45 on the NYSE. This gain followed management discussions at the Goldman Sachs Communacopia + Technology Conference 2026 regarding expected organic growth and integration gains. The stock's performance mirrored a broader upward trend in the S&P 500 index.

Septerna, Inc. announced an inducement grant of a non-qualified stock option to purchase up to 275,000 shares of its common stock to its new Chief Medical Officer, Rajiv Patni, M.D. This grant, effective September 8, 2026, was made under the Company's 2026 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price of $37.37 per share and vests over four years, subject to continuous employment.

Redwood Trust, Inc. (NYSE:RWT) announced a quarterly dividend of $0.18 per share, payable on September 30th to shareholders of record on September 23rd. This represents an annualized dividend of $0.72 and a yield of 20.0%. The company's stock fell 15.5% to $3.60, despite beating earnings estimates last quarter, while analysts maintain a consensus "Hold" rating with an average price target of $5.94.

RCM Technologies, Inc. (RCMT) recently experienced a 2.9% drop, underperforming the broader market despite a 41.27% gain over the past month. Analysts predict strong earnings and revenue growth for the company's upcoming release, with an EPS of $0.63 and revenue of $85.78 million. RCMT currently holds a Zacks Rank of #2 (Buy) and is trading at a discount compared to its industry's average Forward P/E.

Jennifer Newstead, Apple's SVP, General Counsel, and Government Affairs, sold 1,438 shares of AAPL stock for $456,176 on September 8, 2026, as part of a Rule 10b5-1 trading plan. Following the sale, she directly owns 34,352 shares. Apple shares are trading near their 52-week high and are considered overvalued by InvestingPro, despite the recent introduction of a new foldable iPhone model, the Duo.

Redwood Trust (NYSE:RWT) recently hit a new 52-week low of $3.22 before closing at $3.60, amid unusually high trading volume. Analyst sentiment is divided, with an average "Hold" rating and a $5.94 price target, though recommendations range from Buy to Strong Sell. The company exceeded EPS expectations but missed revenue forecasts, and declared a $0.18 quarterly dividend, presenting a high yield but raising questions about its sustainability due to a significantly negative payout ratio.